JP7304878B2 - キャプシド改変による組織特異的遺伝子送達の増加 - Google Patents

キャプシド改変による組織特異的遺伝子送達の増加 Download PDF

Info

Publication number
JP7304878B2
JP7304878B2 JP2020548674A JP2020548674A JP7304878B2 JP 7304878 B2 JP7304878 B2 JP 7304878B2 JP 2020548674 A JP2020548674 A JP 2020548674A JP 2020548674 A JP2020548674 A JP 2020548674A JP 7304878 B2 JP7304878 B2 JP 7304878B2
Authority
JP
Japan
Prior art keywords
modified
aav
aavrh74
viral
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020548674A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019178412A5 (https=
JP2021515572A5 (https=
JP2021515572A (ja
Inventor
スコット アレン ロイラー，
Original Assignee
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル filed Critical リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
Publication of JP2021515572A publication Critical patent/JP2021515572A/ja
Publication of JPWO2019178412A5 publication Critical patent/JPWO2019178412A5/ja
Publication of JP2021515572A5 publication Critical patent/JP2021515572A5/ja
Priority to JP2023104920A priority Critical patent/JP2023115149A/ja
Application granted granted Critical
Publication of JP7304878B2 publication Critical patent/JP7304878B2/ja
Priority to JP2024117744A priority patent/JP2024144521A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2020548674A 2018-03-16 2019-03-14 キャプシド改変による組織特異的遺伝子送達の増加 Active JP7304878B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023104920A JP2023115149A (ja) 2018-03-16 2023-06-27 キャプシド改変による組織特異的遺伝子送達の増加
JP2024117744A JP2024144521A (ja) 2018-03-16 2024-07-23 キャプシド改変による組織特異的遺伝子送達の増加

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862644317P 2018-03-16 2018-03-16
US62/644,317 2018-03-16
PCT/US2019/022353 WO2019178412A1 (en) 2018-03-16 2019-03-14 Increasing tissue specific gene delivery by capsid modification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023104920A Division JP2023115149A (ja) 2018-03-16 2023-06-27 キャプシド改変による組織特異的遺伝子送達の増加

Publications (4)

Publication Number Publication Date
JP2021515572A JP2021515572A (ja) 2021-06-24
JPWO2019178412A5 JPWO2019178412A5 (https=) 2022-03-03
JP2021515572A5 JP2021515572A5 (https=) 2022-03-03
JP7304878B2 true JP7304878B2 (ja) 2023-07-07

Family

ID=67906893

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020548674A Active JP7304878B2 (ja) 2018-03-16 2019-03-14 キャプシド改変による組織特異的遺伝子送達の増加
JP2023104920A Pending JP2023115149A (ja) 2018-03-16 2023-06-27 キャプシド改変による組織特異的遺伝子送達の増加
JP2024117744A Pending JP2024144521A (ja) 2018-03-16 2024-07-23 キャプシド改変による組織特異的遺伝子送達の増加

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023104920A Pending JP2023115149A (ja) 2018-03-16 2023-06-27 キャプシド改変による組織特異的遺伝子送達の増加
JP2024117744A Pending JP2024144521A (ja) 2018-03-16 2024-07-23 キャプシド改変による組織特異的遺伝子送達の増加

Country Status (11)

Country Link
US (2) US12385062B2 (https=)
EP (1) EP3765624A4 (https=)
JP (3) JP7304878B2 (https=)
KR (3) KR20250111395A (https=)
CN (2) CN118373887A (https=)
AU (2) AU2019234918C1 (https=)
BR (1) BR112020018354A2 (https=)
CA (3) CA3293599A1 (https=)
IL (2) IL277270B2 (https=)
SG (1) SG11202008687XA (https=)
WO (1) WO2019178412A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024144521A (ja) * 2018-03-16 2024-10-11 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル キャプシド改変による組織特異的遺伝子送達の増加

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018003665A2 (en) 2015-09-28 2018-09-25 The University Of North Carolina At Chapel Hill methods and compositions for antibody evasion viral vectors
CA3094465A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
CN112543766A (zh) 2018-04-03 2021-03-23 斯特里迪比奥公司 抗体逃避性病毒载体
US20210363191A1 (en) 2018-04-03 2021-11-25 Stridebio, Inc. Antibody-evading virus vectors
BR112021018776A2 (pt) 2019-03-21 2021-11-30 Stridebio Inc Vetores de vírus adenoassociado recombinante
KR20220083714A (ko) 2019-10-17 2022-06-20 스트라이드바이오 인코포레이티드 니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터
EP4200408A1 (en) 2020-08-19 2023-06-28 Sarepta Therapeutics, Inc. Adeno-associated virus vectors for treatment of rett syndrome
US20240299586A1 (en) * 2021-05-06 2024-09-12 The Regents Of The University Of California Novel aav serotypes derived from a library screen
CA3247417A1 (en) 2022-04-06 2023-10-12 Genzyme Corporation TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY
JP2026511976A (ja) * 2023-04-05 2026-04-14 ジェンザイム・コーポレーション Ｄｍ－１筋強直性ジストロフィーの標的遺伝子療法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514427A (ja) 2012-04-18 2015-05-21 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ Ａａｖカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法
JP2016525356A (ja) 2013-07-22 2016-08-25 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 変異ａａｖ、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法
WO2017197355A2 (en) 2016-05-13 2017-11-16 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
CN1856576B (zh) * 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
AU2015335923B2 (en) * 2014-10-21 2021-04-29 University Of Massachusetts Recombinant AAV variants and uses thereof
BR112018003665A2 (en) * 2015-09-28 2018-09-25 The University Of North Carolina At Chapel Hill methods and compositions for antibody evasion viral vectors
AU2017250791B2 (en) * 2016-04-15 2022-11-24 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of micro-dystrophin to treat muscular dystrophy
CN118373887A (zh) 2018-03-16 2024-07-23 国家儿童医院研究所 通过衣壳修饰增加组织特异性的基因递送
WO2020047472A1 (en) 2018-08-30 2020-03-05 Research Institute At Nationwide Children's Hospital Gene therapy for the treatment of galactosemia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514427A (ja) 2012-04-18 2015-05-21 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ Ａａｖカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法
JP2016525356A (ja) 2013-07-22 2016-08-25 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 変異ａａｖ、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法
WO2017197355A2 (en) 2016-05-13 2017-11-16 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIE Qing et al.，The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy，Proc Natl Acad Sci USA, 2002, vol. 99, no. 16, p. 10405-10410

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024144521A (ja) * 2018-03-16 2024-10-11 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル キャプシド改変による組織特異的遺伝子送達の増加

Also Published As

Publication number Publication date
KR20200131843A (ko) 2020-11-24
CN111819286B (zh) 2024-05-24
EP3765624A1 (en) 2021-01-20
IL277270B2 (en) 2025-05-01
SG11202008687XA (en) 2020-10-29
US20210087584A1 (en) 2021-03-25
CA3293598A1 (en) 2026-03-02
IL277270B1 (en) 2025-01-01
CN118373887A (zh) 2024-07-23
AU2025204275A1 (en) 2025-07-03
AU2019234918B2 (en) 2025-08-14
JP2023115149A (ja) 2023-08-18
IL317905A (en) 2025-02-01
JP2024144521A (ja) 2024-10-11
KR20250111395A (ko) 2025-07-22
BR112020018354A2 (pt) 2020-12-29
CN111819286A (zh) 2020-10-23
RU2020131998A (ru) 2022-04-18
US12385062B2 (en) 2025-08-12
EP3765624A4 (en) 2022-05-25
AU2019234918A1 (en) 2020-09-17
KR102834868B1 (ko) 2025-07-17
US20250346924A1 (en) 2025-11-13
KR20250111393A (ko) 2025-07-22
CA3092353A1 (en) 2019-09-19
IL277270A (en) 2020-10-29
JP2021515572A (ja) 2021-06-24
AU2019234918C1 (en) 2026-03-05
WO2019178412A1 (en) 2019-09-19
CA3293599A1 (en) 2026-03-02

Similar Documents

Publication Publication Date Title
JP7304878B2 (ja) キャプシド改変による組織特異的遺伝子送達の増加
US9938541B2 (en) AAV variant
KR102373765B1 (ko) 벡터 제조 및 유전자 전달을 위한 캡시드-결핍 ａａｖ 벡터, 조성물 및 방법
WO2020117898A1 (en) Recombinant adeno-associated viral vector for gene delivery
CN111727243A (zh) 用于跨越血-脑屏障递送病毒载体的方法和组合物
CN111876432B (zh) 一组肝靶向新型腺相关病毒的获得及其应用
JP2023534026A (ja) 多部分遺伝子送達のための組み換えアデノ随伴ウイルスベクター
US12534741B2 (en) Compositions and methods for treatment of neurological disorders
WO2024220719A1 (en) Modified aav capsids for gene delivery
RU2801217C2 (ru) Повышение тканеспецифической доставки генов путем модификации капсида
EP4511496A2 (en) Compositions and methods for treating dominant optic atrophy and x-linked retinoschisis
Kwiatek et al. Directed evolution of AAV capsids for improved efficacy and specificity of delivery to preclinical models of human liver
HK40038424A (en) Methods and compositions for delivery of viral vectors across the blood-brain barrier

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230529

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230627

R150 Certificate of patent or registration of utility model

Ref document number: 7304878

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150